1 / 3

V Vannappagari, 1,2 J Albano, 3 N Koram, 1 H Tilson, 2 AE Scheuerle , 4 M Napier 2

Prenatal Exposure to Zidovudine and Risk for Ventricular Septal Defects and Congenital Heart Defects: Data From the Antiretroviral Pregnancy Registry (APR). V Vannappagari, 1,2 J Albano, 3 N Koram, 1 H Tilson, 2 AE Scheuerle , 4 M Napier 2.

enye
Download Presentation

V Vannappagari, 1,2 J Albano, 3 N Koram, 1 H Tilson, 2 AE Scheuerle , 4 M Napier 2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Prenatal Exposure to Zidovudine and Risk for Ventricular Septal Defects and Congenital Heart Defects: Data From the Antiretroviral Pregnancy Registry (APR) V Vannappagari,1,2 J Albano,3 N Koram,1 H Tilson,2AE Scheuerle,4 M Napier2 1Worldwide Epidemiology, GlaxoSmithKline, RTP, NC, USA; 2Gillings School of Global Public Health, University of North Carolina-Chapel Hill, NC, USA; 3INC Research, Post Approval and Strategic Services, Raleigh, USA; 4Tesserae Genetics, Dallas, TX, USA

  2. Methods Results 16,304 Prospectively reported pregnancies in the APR • Rate and Relative Risk analyses by: • Presence of VSDs: isolated; with CHD only; Multisystem defects • Type and timing of antiretroviral therapy exposure • Particularly differentiation regimens with/without ZDV and with/without NRTIs • Excludes: Chromosome anomalies and/or terminated before 20 wks

  3. Results Conclusions • Prevalence of and risk for VSD and CHD among infants exposed to ZDV-containing regimens is no different from infants exposed to non-ZDV ARV regimens • Among those exposed to ZDV-containing regimens there is no difference in rate of VSD or CHD by trimester of earliest exposure.

More Related